A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression
-
Published:2018-09
Issue:9
Volume:20
Page:894-904
-
ISSN:1476-5586
-
Container-title:Neoplasia
-
language:en
-
Short-container-title:Neoplasia
Author:
Chakravarthi Balabhadrapatruni V.S.K.,
Rodriguez Pena Maria Del CarmenORCID,
Agarwal Sumit,
Chandrashekar Darshan S.,
Hodigere Balasubramanya Sai Akshaya,
Jabboure Fayez J.,
Matoso AndresORCID,
Bivalacqua Trinity J.,
Rezaei Katayoon,
Chaux Alcides,
Grizzle William E.ORCID,
Sonpavde Guru,
Gordetsky JenniferORCID,
Netto George J.,
Varambally Sooryanarayana
Reference50 articles.
1. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018
2. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer;von der Maase;J Clin Oncol,2005
3. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial;Rosenberg;Lancet,2016
4. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial;Sharma;Lancet Oncol,2017
5. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N Engl J Med,2017
Cited by
50 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献